Your alerts 1D 3D 1W 1M 6M 1Y 3Y 5Y Compar Key statistics On Wednesday,Astrazeneca Pharma India Ltd (ASTRAZEN:NSI)closed at 6,665.60, -18.10% below its 52-week high of 8,139.00, set on Oct 07, 2024. 52-week range Today 4,600.70Dec 20 20238,139.00Oct 07 2024 ...
A company profile report for AstraZeneca Pharma India Limited (AZPIL) from publisher Life Science Analytics Inc. is presented, with topics including management profile, company announcements, deals, alliances and product updates.EBSCO_bspAstrazeneca Pharma India Limited Medtrack Company Profile...
AstraZeneca Pharma India的现价与52周高点的百分比值是87.8%. 查看AstraZeneca Pharma India的现价与52周高点的百分比值趋势、图表等
AstraZeneca Pharma India下一财年的预估预期税后净经营利润(nopat)是1.957十亿。. 查看AstraZeneca Pharma India的预期税后净经营利润(NOPAT) (InvestingPro)趋势、图表等
我们发现下列公司与AstraZeneca Pharma India相近,它们都属于相关的行业。我们还考虑了规模、增长和各种财务指标,并将列表缩小到以下范围。 AstraZeneca Pharma India的保险结算基准 名称代码保险结算 AstraZeneca Pharma India NSEI:ASTRAZEN - Medico Remedies Ltd BSE:540937 - Pfizer Ltd BSE:500680 - Abbott India ...
AstraZeneca Pharma India于资产负债表中没有报告,截至六月 30, 2024止最近一个季度存在有意义的应付再保险费。 下表总结了AstraZeneca Pharma India过去五年的应付再保险费和百分比分析(common size): 财政年度应付再保险费资产资产占比 2020-03-31NA7.064 B0.0% ...
2Hoventa Pharma 1Luna Chemicals 1Vio Chemicals 1Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd. ResetOK CAS Number ResetOK Country ResetOK 01 CTX Lifesciences India Post Enquiry Medlab Asia & Asia Health Not Confirmed Post Enquiry 02
AstraZeneca Pharma India Limited has received import and market permission in Form CT-20 from the Drugs Controller General of India for selumetinib 10 mg & 25 mg capsule. Selumetinib 10 mg & 25 mg capsule is indicated for treatment of paediatric patients 3 years of age and older with neurofib...
AstraZeneca Pharma India Ltd a leading biopharmaceutical company announces a change in its leadership with the appointment of Dr. Sanjeev Panchal as Country President & Managing Director, AstraZeneca Pharma India Ltd with effect from 1st January 2023. Sanjeev has been with AstraZe...
AstraZeneca Pharma India Ltd. (AstraZeneca India), a leading biopharmaceutical company, announced the appointment of Bhavana Agrawal as Chief Finance Officer (CFO) with effect from October 1, 2023, following a transition period. She succeeds Rajesh Marwaha, who is retiring as CFO and full-time ...